MedReleaf Corp. (OTCPNK: MEDFF) is an R&D-driven company dedicated to innovation, operational excellence and the production of industry-leading, top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state-of-the-art ICH-GMP and ISO 9001 certified facilities in Ontario, with a third facility currently in development, a full range of premium MedReleaf products are delivered to the global medical market.

 

Product Portfolio:

 

In the recent past, MEDFF has well positioned itself to be one of the most significant suppliers to the therapeutic needs of patients seeking safe, consistent and effective medical cannabis and provide a compelling product offering for the adult-use recreational market. The company continues to set new records for sales and volume, introduced brands for the adult-use market, expanded its international presence, commercialized new proprietary cannabis varieties, more than doubled its production capacity and MedReleaf was named Top Licensed Producer at the 2017 Canadian Cannabis Awards.

 

Recent highlights and achievements:

• Aurora Cannabis Inc. (“Aurora”) agreed to acquire all of the issued and outstanding common shares of MedReleaf for 3.575 common shares of Aurora and $0.000001 in cash in exchange for each MedReleaf common share held.
• On May 14, 2018, Aurora Cannabis Inc. (“Aurora”) and the Company entered into an arrangement agreement, pursuant to which Aurora will acquire all of the outstanding common shares of the Company and each shareholder of the Company will be entitled to receive 3.575 common shares of Aurora and $0.000001 in cash in exchange for each Common Share held.
• Entered into a Memorandum of Understanding (“MOU”) with the British Columbia Liquor Distribution Branch (“BCLDB”) to supply the Province with high-quality adult recreational-use cannabis products.
• Received certification under the European Medical Agency’s Good Manufacturing Practices (“EU GMP”) Standards for its Markham facility from authorities in Cologne, Germany to make the first export of its products into Germany and has completed its first shipment of medical cannabis to Cannamedical Pharma GmbH (“Cannamedical”).
• Completed a supply agreement with the Alberta Gaming, Liquor & Cannabis Commission (“AGLC”) to supply high-quality adult recreational-use cannabis products.
• Completed a supply agreement with Société des alcools du Québec (“SAQ”) to supply the future Société québécoise du cannabis (“SQDC”) with 8 tons of cannabis products per year for a minimum three-year term.
• Completed the purchase of a 164-acre property in Exeter, Ontario, including a 1 million square foot greenhouse to be retrofitted for cannabis production with an estimated production capacity of up to 105,000 kilograms annually.
• Launched AltaVie, the Company’s second premium brand for the adult-use market.

Key Synergies/value unlocking with the combination of Aurora and MedReleaf – The merger is expected to yield many important strategic synergies in all areas of business, marketing, and operations, allowing for accelerated growth:

• Industry-leading scale: Funded capacity will increase to over 570,000 kg of high-quality cannabis per year, to be delivered through nine facilities in Canada and two in Europe
• Low production costs and industry-leading yields: Aurora’s automated ‘Sky Class’ greenhouses are expected to deliver industry-leading efficiencies and ultra-low production costs of well below $1 per gram, delivering sustainably robust margins. MedReleaf’s high-yield cultivation techniques are expected to enhance productivity further and reduce costs across the combined entity’s facilities.
• International distribution: Aurora has established a strong and rapidly growing footprint in the international medical market. The combined entity is now well-positioned to rapidly gain market share in a number of significant markets. Most notable among these is the European Union, which will have in excess of 400 million people following Brexit.
• Expanding brand leadership: Aurora, CanniMed, and MedReleaf represent three well-established medical cannabis brands, and a growing portfolio of premium consumer and wellness brands including San Rafael ’71, Woodstock, and AltaVie that are backed by detailed consumer and marketplace insights and advanced analytical frameworks. This brand leadership positions the combined entity well to drive accelerated growth through its existing distribution channels for the domestic medical and consumer markets, as well as the international medical markets.
• Scientific leadership: Each company is actively engaged in clinical trials and medical studies, which has resonated strongly with the international medical community, driving above-average prescription rates and referrals.
• R&D: The combined company will have an industry leading Science and Research & Development team. Combining these capabilities will accelerate product development and technology adoption, creating strong, defensible competitive advantages, including, management believes higher-margin offerings to drive above-average profitability.

Over the years, MedReleaf has proven itself as a benchmark for global cannabis entities. In fact, the company has consistently grown since its inception and now with the recent strategic developments, MedReleaf is well poised to become an established conglomerate spanning across production, retailing, ancillary and adjacent markets. Additionally, the company’s merger with Aurora will shorten it’s time to market its premium medical cannabis products to domestic and global markets, and compelling brands to the adult-use recreational market.

 

Taking all this into consideration, the market cap of just $2.02 billion and share now ruling at $19.59, can move to a level of about $30.79. Source: www.marketwatch.com

 

About Aurora: Headquartered in Edmonton, Alberta, with funded capacity in excess of 430,000 kg per year and sales and operations in 14 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

 

Other business highlights/recent achievements of MedReleaf:

• Introduced Equiposa, Orellium, and Trutiva – three proprietary varieties of premium medical cannabis developed by MedReleaf’s internal R&D program.
• On January 31, 2018, MedReleaf closed a short form prospectus offering on a “bought deal basis,” pursuant to which the Company issued an aggregate of 5,000,000 units of the Company at a price of $26.50 per Unit for aggregate gross proceeds of $132,500.
• Received Health Canada approval for and launched the first color-coded and strain-specific cannabis oil softgel capsules on the market.
• Launched San Rafael ’71 TM, the Company’s first brand for the adult-use market. To mark the launch and to introduce Canada to the San Rafael ’71 TM brand, the Company developed and launched in partnership with Amsterdam Brewing the first San Rafael ’71 TM product – 4:20 Pale Ale.
• Entered into an exclusive licensing agreement with Woodstook Cannabis Company for the use of the iconic Woodstock brand in the Canadian cannabis market.
• Signed an agreement to become the largest supplier to Cannamedical Pharma GmbH, a leading medical cannabis distributor in Germany with a network of over 1,800 pharmacies.

Latest Quarter Financial position: 

 

Revenues Sales for the three months ended March 31, 2018, were $12.0 million and increased $1.7 million or 16% compared to the three months ended March 31, 2017, of$10.4 million. Sales for the year ended March 31, 2018, were $43.6 million and increased $3.3 million or 8% compared to the year ended March 31, 2017, of $40.3 million.

 

Sales growth was primarily the result of increased production capacity, patient demand, yield improvements, and the continued growth of cannabis oil extracts for sale. Throughout the year ended March 31, 2018, and 2017, the Company’s Markham Facility was operating at full capacity (based on square footage). In November 2016, Health Canada approved the Company to produce and sell cannabis oil extracts.

 

Profitability: Adjusted EBITDA loss of $4.7 million, a decrease of $6.3 million from the prior year period due to increased overhead costs and investments in recreational brands, international business initiatives, and increased research and development efforts. Net loss for the three and twelve months ended March 31, 2018, was $0.8 million and $7.5 million (2017 – net income of $2.2 million and $11.0 million), respectively.

Liquidity: At the end of March 31, 2018, the Company had cash and cash equivalents of $215.9 million and working capital of $255.7 million.

 

 

Key risk factors and potential stock drivers:

• MEDFF is still an early stage cannabis company. Therefore, its ability to ramp up operations/profitability, as it grows its market position and seeks ways to monetize it would be a key value driver for the company and its shareholders.

 

• It said the company is likely to see meaningful results from their current developments. Analysts remain hopeful that these payoffs will take shape quite soon and stay bullish about the stock price.

 

• Regulatory Risk: Notwithstanding the current operational and marketing progress, the company continues to remain exposed to regulatory and legal risk. In this sector, the regulatory framework and science are rapidly changing and evolving. Therefore, new companies are emerging, and regulatory risk always exists for the players in the industry.

 

• MEDFF’ ability to maintain liquidity and financial flexibility to fund its incremental capital requirements will remain crucial for the company. Additionally, the industry is competitive, and MEDFF will be competing with many other and better-financed companies.

 

Stock Chart:

Comments:

• On Friday, July 20^th, 2018, MEDFF closed at $19.59, on an above average volume of 167,342 shares exchanging hands. Market capitalization is $2.02 billion. The current RSI is 41.04.
• In the past 52 weeks, shares of MEDFF have traded as low as $5.86 and as high as $24.99
• At $19.59, shares of MEDFF are trading below its 50-day moving average (MA) at $20.57 and significantly above its 200-day moving average (MA) at $15.77
• The present support and resistance levels for the stock are at $18.6033 & $20.9833 respectively.

 

 

Disclaimer

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.